BioNumerik’s Tavocept Fails In Neuropathy, Adds To Survival Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is looking for commercialization partner for cancer candidates, CEO tells “The Pink Sheet” DAILY.